Home|Journals|Articles by Year|Audio Abstracts
 

Case Report

EJMCR. 2018; 2(1): 33-37


Capecitabine-induced vasospasm: a case report

Fayez El Shaer, Ismail R Raslan, Waleed Al Habeeb, Mostafa AlShimiri, Hanan AlBaker, Khaled Al Habib.




Abstract
Cited by 0 Articles

Background: Coronary heart disease with acute coronary syndrome (type II myocardial infarction) may be an iatrogenic and a reversible cause with complete recovery after cessation of the accused agent.
Case presentation: We present the case of a 52-year-old male patient who had received adjuvant chemotherapy consisting of capecitabine, 3 mg orally once per day, after resection of moderately differentiated invasive adenocarcinoma in the transverse colon. Three days (3 doses) after the initiation of chemotherapy, the patient reported typical anginal chest pain and an electrocardiogram (ECG) indicated ST-segment elevation. A repeat ECG in the catheterization laboratory showed normal results. Echocardiography showed that left ventricular systolic function was moderately to severely reduced. Coronary angiography revealed normal coronary arteries.
Conclusion: Capecitabine should be used with caution, as patients receiving this medication might present with symptoms suggestive of acute coronary syndrome that might not always originate from epicardial coronary artery disease. There is always a possibility of vasospasm when a patient is receiving Capecitabine.

Key words: Keywords: Vasospasm, Chemotherapy, Capecitabine, case-report






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.